SCHEMBL6708255

SCHEMBL6708255

CC(C)(C)OC(=O)N1CCC(C2CCN(C(=O)NCCc3ccc(CN4CCCC4)cc3)CC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPSAB1 Q15661 2/20 0.48
TPSD1 Q9BZJ3 2/20 0.48
TPSG1 Q9NRR2 2/20 0.48
GPR119 Q8TDV5 7/20 0.47
F2 P00734 1/20 0.46
PLG P00747 1/20 0.46
PRSS1 P07477 1/20 0.46
CYP2D6 P10635 1/20 0.43
CHRM1 P11229 1/20 0.43
HTR2A P28223 1/20 0.43
MCHR1 Q99705 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPN6 P29350 1/20 0.43
TP53 P04637 1/20 0.43
CHRM4 P08173 1/20 0.43
ABL1 P00519 1/20 0.43
RIN1 Q13671 1/20 0.43
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6248252 0.88 TPSAB1 (0.41) TPSAB1TPSD1TPSG1F2PLG
SCHEMBL6705906 0.85 MCHR1 (0.52) TPSAB1TPSD1TPSG1CYP2D6CHRM1
SCHEMBL27478382 0.79 ALDH1A1 (0.51) GPR119PTPN2PTPN1PTPN6TP53
SCHEMBL3868915 0.79 NAMPT (0.54) CYP2D6CHRM1HTR2AMCHR1KDM4E
SCHEMBL6704726 0.77 MAPT (0.56) CYP2D6CHRM1HTR2AMCHR1TP53
SCHEMBL6704534 0.77 L3MBTL3 (0.59) TPSAB1TPSD1TPSG1CYP2D6CHRM1
SCHEMBL6706014 0.76 CHRM4 (0.54) CYP2D6CHRM1HTR2AMCHR1CHRM4
SCHEMBL4016101 0.76 CA12 (0.63) PTPN2PTPN1PTPN6ABL1RIN1
SCHEMBL18083773 0.76 MAPT (0.65) KDM4E
SCHEMBL6705916 0.75 CHRM4 (0.69) CHRM1MCHR1CHRM4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040242572-A1 New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242572-A1 New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture MCHR2, MCHR1, NPY1R TPSAB1 279/4885TPSD1 184/4885TPSG1 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.